ERAD is the official Journal of the Institute of Rheumatic and Autoimmune Diseases (INRADIS)

Journal type: e-Journal, Open access
Published by: INRADIS (Institute of Rheumatic and Autoimmune Diseases)
Language: English

Editor-in-Chief: Professor Dimitrios P. Bogdanos
Honorary Editor in Chief: Professor Lazaros I. Sakkas

Excellence of Rheumatic and Autoimmune Diseases (ERAD) is a peer reviewed, International journal dedicated to the dissemination of cutting-edge experimental, translation and clinical research in the fields of Autoimmune Diseases, Rheumatology and Clinical Immunology.

The Journal is published On line (e-Journal) and is an Open Access Journal.

All accepted papers are published free of charge and no publication or other fees directly or indirectly related to publication are requested by the participating Authors or their Institutions.

ERAD publishes original research articles, case reports, editorials, commentaries, reviews, letters and images on all aspects of clinical and experimental autoimmune and rheumatic diseases.

The goal of this Journal is to keep a record of the state-of-the-art research and to promote information and knowledge about study, research, clinical practise and on-going developments within its various specialties and sub-specialties related to the field of autoimmunity, rheumatology and clinical immunology.

All manuscripts submitted to ERAD must be original, previously unpublished and may not be considered for publication elsewhere at any time during ERAD review period.

In general, accepted articles will appear online within 3-4 weeks upon acceptance. The journal publishes original papers including but not limited to the following fields:

  • Clinical Medicine
  • Experimental Medicine
  • Clinical, Translation and Experimental Immunology
  • Translational Immunology
  • Autoimmunology
  • Therapeutics
  • Immunotherapy
  • Biologics
  • Immunopathogenesis
  • ImmunoOmics

  • Excellence on the latest advancements in Rheumatology, Autoimmune Diseases and Clinical and Experimental Immunology are published
  • Excellence on Aetiology and Pathogenesis of autoimmunity
  • Excellence on Clinical, experimental and translational research aspects of organ-specific and non-organ specific Autoimmune diseases
  • Excellence on the criteria of diagnosis of autoimmune diseases and immunodeficiencies
  • Excellence on Environmental, genetic and epigenetic factors of Autoimmune and Rheumatic Diseases
  • Excellence on Complications, short and long term Side effects of treatment regimens
  • Excellence on Vaccination and prophylaxis
  • Excellence on Diagnosis, prognosis, management
  • Excellence on Laboratory, clinical and experimental aspects of the disease
  • Experimental models
  • Excellence on New therapeutic strategies in the management of difficult to treat autoimmune diseases
  • Excellence on The emergence of new signs, tests and biomarkers as diagnostic, and prognostic tools
  • Excellence on The increasing use of biologic drugs and new biologic drugs in evolution
  • Excellence on Treatment and management of comorbidities
  • Excellence on Clinical trials, failures and successes
  • Excellence on Unmet needs in Rheumatology, Autoimmunology and Clinical Immunology practice
  • Excellence on the diagnosis of emerging immune-mediated and autoimmune diseases
  • Excellence on the management and evidence-based medicine related to autoimmune and rheumatic disorders

The Journal accepts and publishes all types of papers, including but not limited to original research articles, case reports, editorials, commentaries, reviews, letters and images on all aspects of clinical and experimental autoimmune and rheumatic diseases.

Short papers are pee-reviewed in a fast track process and if accepted are published in press within 10 days.

Authors of selected short papers would be invited to write a regular paper on the same topic for future issues of the Journal.